Status:
RECRUITING
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Lead Sponsor:
Mediar Therapeutics
Conditions:
Idiopathic Pulmonary Fibrosis
Eligibility:
All Genders
40+ years
Phase:
PHASE2
Brief Summary
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
Detailed Description
Participants with IPF who meet the study's inclusion and exclusion criteria will be randomly assigned in a 1:1 ratio to receive MTX-463 or a matching placebo by intravenous (IV) infusion. Concomitant ...
Eligibility Criteria
Inclusion
- Participants with IPF of any gender ≥ 40 years of age at time of signing the informed consent.
- Able to understand the study and provide signed, written informed consent.
- Able to read and understand the language of the informed consent and other trial-related materials.
- Meet the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Association (ATS/ERS/JRS/ALAT) 2019 criteria for the diagnosis of IPF; Diagnosed with IPF within 7 years of screening.
- If a participant is on treatment with pirfenidone or nintedanib, the dose of the medication must be stable for ≥ 90 days prior to Screening with plans to maintain the same dose throughout the study treatment period. Use of both agents together is not permitted.
- If a participant was on treatment with nintedanib or pirfenidone, and the agent has been discontinued, this must have occurred ≥ 30 days prior to Screening. At Screening, there must also be no plan to start either of these medications for the duration of the study.
- FVC of ≥ 45 percent predicted (pp) at screening.
- DLCO of ≥ 25pp at screening.
- Willing and able to complete all protocol required study visits and procedures.
- All participants of childbearing potential must have a negative serum pregnancy test at Screening.
- Participants with reproductive potential must agree to use and follow medically approved contraceptive precautions during the study
Exclusion
- Acute exacerbation of IPF within 6 months of Screening or during the Screening Period.
- Forced expiratory volume in 1 second (FEV1)/FVC ratio of \<0.7 at Screening.
- Requirement for continuous supplemental oxygen. Intermittent supplemental oxygen use (e.g., during exercise or sleep) is permitted.
- Expected to receive a lung transplant within the study duration.
- Current active bacterial infection or use of antibiotics for suspected lung infection in the 30 days prior to Screening.
- Planned surgery within the study duration.
- Clinically significant pulmonary hypertension.
- Use of immunosuppressive therapy (excluding corticosteroids). If previously on such agents, they should have been discontinued for at least 5 half-lives or 90 days, whichever is longer, prior to Screening.
- Use of systemic corticosteroids (prednisone or equivalent) at a dose ≥ 10 mg once daily within 30 days of Screening.
- Currently smoking or vaping.
- Current known malignancy, or history of cancer, or lymphoproliferative disorder other than non-melanomatous skin cancers, within 2 years of Screening.
- Current infection with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).
- Currently pregnant, breast feeding, or planning to conceive for the length of the study.
- History of severe depression, psychosis, or suicidal ideation, as determined by the Investigator, within 2 years of Screening.
- Any clinically significant disease or laboratory abnormality detected at Screening that might interfere with a participant's ability to complete the study, on-study evaluations, or participant safety.
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2× upper limit of normal (ULN) at Screening.
- Any other concurrent active medical condition determined by the Investigator to interfere with participant's ability to complete the trial.
- Known allergy to MTX-463 or any of its excipients.
- Any prior use of MTX-463 or other therapy targeting WISP1.
- Any other concurrent experimental agent or an active part of any other clinical trial, unless they have stopped taking the investigational product at least 5 half-lives or 30 days before Screening, whichever is longer.
Key Trial Info
Start Date :
May 5 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2027
Estimated Enrollment :
164 Patients enrolled
Trial Details
Trial ID
NCT06967805
Start Date
May 5 2025
End Date
August 1 2027
Last Update
January 7 2026
Active Locations (32)
Enter a location and click search to find clinical trials sorted by distance.
1
WISPer Site in Birmingham, AL
Birmingham, Alabama, United States, 35233
2
WISPer site in Phoenix, AZ
Phoenix, Arizona, United States, 85032
3
WISPer Site in Los Angeles, CA
Los Angeles, California, United States, 90033
4
WISPer site in Newport Beach, CA
Newport Beach, California, United States, 92663